source
- FDA clears Lantheus' Tauklarify PET imaging agent for Alzheimer’s tau detectionLantheus received FDA clearance for its PET imaging agent Tauklarify, also known as MK-6240, which is designed to help diagnose Alzheimer’s disease by visualizing tau protein deposits. The clearan…
- Celcuity waits on FDA review of second plant as cancer drug rollout lags expectationsCelcuity has announced that it is awaiting the U.S. Food and Drug Administration’s review of a second manufacturing facility needed for its newly approved cancer therapy. The company explained tha…